Contrasting VBI Vaccines (NASDAQ:VBIV) & Xilio Therapeutics (NASDAQ:XLO)

VBI Vaccines (NASDAQ:VBIV) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Risk and Volatility

VBI Vaccines has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500.

Earnings & Valuation

This table compares VBI Vaccines and Xilio Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VBI Vaccines	$9.41 million	1.97	-$92.84 million	N/A	N/A
Xilio Therapeutics	N/A	N/A	-$76.40 million	($2.57)	-0.35

Xilio Therapeutics has lower revenue, but higher earnings than VBI Vaccines.

Profitability

This table compares VBI Vaccines and Xilio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VBI Vaccines	-881.79%	-525.42%	-45.87%
Xilio Therapeutics	N/A	-153.48%	-89.26%

Insider and Institutional Ownership

12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for VBI Vaccines and Xilio Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VBI Vaccines	0	0	0	0	N/A
Xilio Therapeutics	0	0	1	0	3.00

Summary

Xilio Therapeutics beats VBI Vaccines on 5 of the 9 factors compared between the two stocks.

About VBI Vaccines

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.